Abstract
Drug-induced proarrhythmia is a serious medical problem that causes relevant morbidity and mortality. It is also a relevant problem for the development of novel pharmacological compounds. Therefore, there is a need for sensitive, specific and high-throughput preclinical tests to detect a risk for drug-induced proarrhythmia early in the development of new drugs. The review focuses on the potential role of transgenic models with altered repolarisation but without overt structural heart disease for drug-induced proarrhythmia screening. Today, selected murine models with alterations in K+, Na+ channels and ankyrin are available. In the future, transgenic rabbit and Zebra fish models may also be used.
Original language | English |
---|---|
Pages (from-to) | 289-94 |
Number of pages | 6 |
Journal | Cardiovascular & Hematological Agents in Medicinal Chemistry |
Volume | 5 |
Issue number | 4 |
DOIs | |
Publication status | Published - Oct 2007 |
Keywords
- Action Potentials
- Animals
- Animals, Genetically Modified
- Anti-Arrhythmia Agents
- Arrhythmias, Cardiac
- Disease Models, Animal
- Drug Design
- Humans
- Mice
- Potassium Channels
- Sodium Channels